FRESENIUS SE & CO. K

FRE
Real-time Estimate Quote. Real-time Estimate  - 01/20 03:59:46 pm
39.09EUR +0.93%

Fresenius : Kabi launches its first specialty IV drug in the U.S.

12/01/2020 | 10:21am

Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company's generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient's home or doctor's office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

Disclaimer

Fresenius SE & Co. KGaA published this content on 01 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2020 15:20:01 UTC

© Publicnow 2021
Copier lien
All news about FRESENIUS SE & CO. KGAA
1d ago
1d ago
2d ago
2d ago
7d ago